The funds will be used to expand patient access and accelerate innovation, opening opportunities to explore indications beyond essential tremor, including other neurological indications like Parkinson’s disease as well as targets in psychiatry, cardiology and autoimmune disorders.

“Baird Capital’s Venture team is proud to continue supporting Cala Health,” said Amy Len Kobe, Principal with Baird Capital. “We are eager to see Cala Health’s continued growth and impact on those affected by chronic diseases through cost-saving, non-invasive technologies.”

Baird Capital initially invested in Cala Health in 2019. For the full news release related to today’s announcement, click here.